The FDA grants fast track designation to PHST001, an antibody targeting CD24, for advanced platinum-resistant and ...

A new study explains the genetic underpinnings of a rare and aggressive form of ovarian cancer – and offers a potential ...

Adding IMNN-001 to perioperative chemotherapy showed numerical improvements in PFS and OS for newly diagnosed epithelial ...

In addition, mirvetuximab soravtansine (Elahere) was the first targeted therapy to demonstrate an improvement in OS in ...

Relacorilant/nab-paclitaxel significantly improved PFS and OS vs nab-paclitaxel alone in platinum-resistant ovarian cancer.

Relacorilant blocks GR activation, a key pathway driving stress-induced chemoresistance in ovarian cancer cells.

Results, presented simultaneously in oral presentation at ASCO 2025 and in peer-reviewed Gynecologic Oncology, suggest very meaningful survival effect of IMNN-001 in women HRP and HRD positive, ...

Researchers compare relacorilant plus nab-paclitaxel with nab-paclitaxel monotherapy in patients with platinum-resistant ...

Drugmakers are turning to biomarkers, like folate receptor alpha, and even cell therapies to tackle this deadly cancer in new ...

chemotherapy is a type of ovarian cancer treatment in which chemo drugs are directly pumped into your belly cavity (also called peritoneal cavity). When you get chemo this way, it allows a more ...

Evidence-based recommendations on olaparib (Lynparza) for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line ...

platinum-resistant epithelial ovarian, fallopian tube, or peritoneal cancer. The FDA granted accelerated approval for Elahere in Nov. 2022, according to an agency press release. Other ADCs in ...